Trial in progress: A first-in-human phase 1/2 study of hematopoietic stem cell transplantation (HCT) with VOR33 (CD33-deleted allograft) followed by treatment with gemtuzumab ozogamicin (GO) in patients with CD33+ acute myeloid leukemia (AML) who are at high-risk of post-HCT relapse Meeting Abstract
| Authors: | Cooper, B. W.; Suh, H. C.; Koura, D.; Koehne, G.; Cho, C.; Bambace, N. M.; Bernard, L.; Shah, N. N.; Walter, R. B.; DiPersio, J. F.; Nath, S.; Lee-Sundlov, M. M.; Lacy, A.; Stanizzi, D.; Kuhn, K.; Whangbo, J. S.; Slapak, C.; Raffel, G. D. |
| Abstract Title: | Trial in progress: A first-in-human phase 1/2 study of hematopoietic stem cell transplantation (HCT) with VOR33 (CD33-deleted allograft) followed by treatment with gemtuzumab ozogamicin (GO) in patients with CD33+ acute myeloid leukemia (AML) who are at high-risk of post-HCT relapse |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 12973 |
| End Page: | 12975 |
| Language: | English |
| ACCESSION: | WOS:000893230305499 |
| DOI: | 10.1182/blood-2022-165289 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
